Steady sure airway power “is right here to stick,” sleep medication physician Atul Malhotra declared in a Would possibly 2024 editorial revealed within the Lancet.
However after Eli Lilly reported the whole result of its weight problems drug in sleep apnea sufferers closing week, trade watchers are actually debating the lasting energy of CPAP machines. The trial, run through Malhotra himself, demonstrated that Zepbound diminished the selection of sleep apnea episodes in sufferers each who have been the usage of the machines and people who weren’t.
Traders unexpectedly reacted after the information liberate on overdue Friday. On Monday, stocks of main CPAP maker ResMed dropped 11% and stocks of nerve stimulator Encourage sank 17%. However trade analysts and medical professionals are cut up on whether or not that is some other instance of “Ozempic panic,” or a valid caution of CPAP’s eventual decline.
STAT+ Unique Tale
Have already got an account? Log in
This text is unique to STAT+ subscribers
Liberate this newsletter — and get further research of the applied sciences disrupting well being care — through subscribing to STAT+.
Have already got an account? Log in
Have already got an account? Log in
Particular person plans
Staff plans
View All Plans
Get limitless get entry to to award-winning journalism and unique occasions.
Subscribe
